Supreme Strengthens Management Team With Appointment of New Director

NOVEMBER 19, 2015


Thursday, November 19 2015, Toronto, ON – Supreme Pharmaceuticals Inc. (the “Company” or “Supreme“) (OTC PINK:SPRWF)(CSE:SL) is pleased to announce the appointment of Navdeep Dhaliwal to the Company’s Board of Directors. Mr. Dhaliwal’s primary focus will be the development of Supreme’s go-to-market strategy in addition to corporate development and capital markets initiatives. “This is an exciting time for Supreme. I am looking forward to working with Supreme’s leadership team to leverage my experiences growing businesses, particularly in the online space,” said Mr. Dhaliwal.

Mr. Dhaliwal is a Chartered Accountant and currently serves as the principal of NLX Capital Corp., a Toronto-based corporate development firm focused primarily on technology and renewable energy. Mr. Dhaliwal was recently retained by a Toronto software company where he successfully expanded the company’s business into South East Asia, where Mr. Dhaliwal has extensive business experience.

Mr. Dhaliwal has been involved in the Canadian medical marijuana space for two years prior to joining Supreme and states: “I believe there is a strong positive outlook for the Canadian marijuana industry, particularly amongst producers harnessing the power of sunlight to reduce costs and improve sustainability.”

Concurrent with Mr. Dhaliwal’s appointment, the Supreme’s Board of Directors accepted the resignation of Allan Levien, a long serving director of the Company. Supreme thanks Mr. Levien for his years of dedicated service and wishes him the best in all of his present and future endeavours. Supreme’s President, John Fowler commented: “Mr. Levien was instrumental in transitioning Supreme into the cannabis industry and I am thankful for his vision. I am also very excited to welcome Mr. Dhaliwal to Supreme’s Board of Directors, as he will play an integral role for us as we plan to hit the ground running in the next phase of our business development.”

About Supreme

Supreme is a Canadian publically traded company committed to becoming a leading supplier of affordable medical cannabis achieved by applying commercial agriculture practices to medical cannabis production. Supreme’s flagship facility is a 342,000 sq. ft. hybrid greenhouse located in Kincardine, Ontario, which has been designed to maximize production efficiencies allowing the Company to pass savings along to its future patients.


This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the timing on competition of the MMPR License conditions for its Southern Ontario facility and the start of production. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on and such factors as the Company failing to acquire final MMPR licenses and put the same into production. This news release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995.

Contact Information

Investor Relations
202 – 20 De Boers Dr, Toronto ON
M3J 0H1

Phone: (416) 630-7272